November 12, 2019 Nearly 90 Percent of PsA Patients Who Use Complementary Medicines Report Benefits More than half of patients in a psoriatic arthritis (PsA) cohort who met validated classification criteria for the disease reported using some form of complementary or alternative medicine (CAM) in a 12-month period, researchers reported November 12 at the annual meeting of the American College of Rheumatology in Atlanta. Read more   ADVERTISEMENT EU Consensus Statement on Combined Therapy with Methotrexate Methotrexate (MTX) should be continued in most patients with active rheumatoid arthritis (RA) when biologic or targeted synthetic therapy is initiated, EU researchers reported in a poster presentation on November 12 at the annual meeting of the American College of Rheumatology in Atlanta. Read more   Olokizumab May Offer New Option for RA Patients The anti-IL-6 agent olokizumab was safe and effective when added to methotrexate in patients with rheumatoid arthritis (RA) in a phase 3 randomized controlled trial, researchers reported on November 12 at the American College of Rheumatology annual meeting in Atlanta.   Combination Treatment at Full Dose Best for RA Patients with early rheumatoid arthritis (RA) and serological biomarkers of a poor prognosis who initiated treatment with abatacept plus methotrexate sustained remission across all arms of a 48-week dose de-escalation trial, though the full combination produced the best maintenance, researchers reported November 12 at the American College of Rheumatology annual meeting in Atlanta.